This CME program is derived from content presented at the 2024 Eastern Pulmonary Conference. The expert faculty, Dr. Jeffrey B. Hoag, will first review the pathophysiology, diagnostic strategies, and unmet needs for patients with non-cystic fibrosis bronchiectasis (NCFBE). Following, he will analyze clinical trial data for NCFBE therapeutics, including DPP1 inhibitor therapeutics. Lastly, Dr. Hoag will discuss how to apply current science to treatment plans to treat NCFBE.
Pulmonologists and other healthcare professionals involved in the treatment and management of patients with NCFBE
Review the pathophysiology, diagnostic strategies, and unmet needs for patients with NCFBE
Analyze clinical trial data for NCFBE therapeutics including DPP1 inhibitor therapeutics
Apply current science to treatment plans to treat NCFBE regardless of baseline disease severity
Pathophysiology, Diagnostic Strategies, and Unmet Needs of Patients with NCFBE
Clinical Trial Analysis of NCFBE Treatments, Including DPP1 Inhibitor Therapeutics
Applying Current Science to Treatment Plans for NCFBE Regardless of Baseline Disease Severity
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Jeffrey B. Hoag, MD | Nothing to disclose |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Insmed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Insmed do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606